Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
ALVAL.PA
Top 10 Correlated ETFs
ALVAL.PA
Top 10 Correlated Stocks
ALVAL.PA
Financial details
Company Rating
Neutral
Market Cap
45.42M
Income
-5.37M
Revenue
1.35M
Book val./share
1.01
Cash/share
0.83
Dividend
-
Dividend %
-
Employees
5K
Optionable
No
Shortable
Yes
Earnings
30 Sep 2022
P/E
-3.88
Forward P/E
-
PEG
-0.29
P/S
12.82
P/B
1.74
P/C
4.41
P/FCF
-3.28
Quick Ratio
2.03
Current Ratio
2.64
Debt / Equity
0.86
LT Debt / Equity
0.58
-
-
EPS (TTM)
-1.21
EPS next Y
-
EPS next Q
-
EPS this Y
-83.89%
EPS next Y
-
EPS next 5Y
-33.02%
EPS last 5Y
-34.11%
Revenue last 5Y
33.01%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-20.31%
SMA50
-36.52%
SMA100
-40.75%
Inst Own
-
Inst Trans
-
ROA
-23%
ROE
-43%
ROC
-0.32%
Gross Margin
92%
Oper. Margin
-375%
Profit Margin
-398%
Payout
-
Shs Outstand
9.72M
Shs Float
8.67M
-
-
-
-
Target Price
-
52W Range
3.52-7.45
52W High
-47.71%
52W Low
+22%
RSI
29.15
Rel Volume
1.04
Avg Volume
6.35K
Volume
6.6K
Perf Week
0.83%
Perf Month
-17.57%
Perf Quarter
-44.38%
Perf Half Y
-43.69%
-
-
-
-
Beta
0.6573
-
-
Volatility
0.07%, 0.45%
Prev Close
0%
Price
3.66
Change
-1.08%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.13 | 0.38 | 0.28 | 0.58 | 0.02 | |
| Net income per share | -0.67 | -1.31 | -1.17 | -0.51 | -0.08 | |
| Operating cash flow per share | -0.59 | -1.19 | -1.05 | 0.36 | -0.07 | |
| Free cash flow per share | -0.76 | -1.42 | -1.11 | 0.32 | -0.07 | |
| Cash per share | 2.89 | 1.95 | 1.71 | 1.96 | 0.21 | |
| Book value per share | 2.77 | 1.95 | 1.76 | 0.96 | 0.14 | |
| Tangible book value per share | 2.68 | 1.8 | 1.59 | 0.84 | 0.13 | |
| Share holders equity per share | 2.77 | 1.95 | 1.76 | 0.96 | 0.14 | |
| Interest debt per share | 0.48 | 0.76 | 1.09 | 1 | 0.07 | |
| Market cap | 28.34M | 15.28M | 14.47M | 50.23M | 667.16M | |
| Enterprise value | 19.44M | 10.66M | 11.21M | 42.65M | 652.93M | |
| P/E ratio | -11.6 | -3.08 | -2.63 | -13.12 | -76.85 | |
| Price to sales ratio | 57.61 | 10.43 | 11.05 | 11.55 | 325.76 | |
| POCF ratio | -13.05 | -3.36 | -2.93 | 18.65 | -93.23 | |
| PFCF ratio | -10.11 | -2.84 | -2.76 | 21.27 | -88.05 | |
| P/B Ratio | 2.79 | 2.06 | 1.75 | 7.02 | 46.67 | |
| PTB ratio | 2.79 | 2.06 | 1.75 | 7.02 | 46.67 | |
| EV to sales | 39.51 | 7.28 | 8.56 | 9.81 | 318.81 | |
| Enterprise value over EBITDA | -8.45 | -2.3 | -2.66 | -17.99 | -86.93 | |
| EV to operating cash flow | -8.95 | -2.34 | -2.27 | 15.84 | -91.24 | |
| EV to free cash flow | -6.93 | -1.98 | -2.14 | 18.06 | -86.17 | |
| Earnings yield | -0.09 | -0.33 | -0.38 | -0.08 | -0.01 | |
| Free cash flow yield | -0.1 | -0.35 | -0.36 | 0.05 | -0.01 | |
| Debt to equity | 0.15 | 0.31 | 0.45 | 0.7 | 0.43 | |
| Debt to assets | 0.2 | 0.38 | 0.45 | 0.66 | 0.5 | |
| Net debt to EBITDA | 3.87 | 1 | 0.77 | 3.2 | 1.89 | |
| Current ratio | 12 | 4.36 | 3.66 | 1.98 | 3.17 | |
| Interest coverage | -31.33 | -58.57 | -14.33 | -8 | -37.01 | |
| Income quality | 0.89 | 0.92 | 0.9 | -0.7 | 0.82 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.32 | 0.79 | 1.14 | 0.25 | 0.6 | |
| Research and developement to revenue | 2.29 | 1.21 | 3.03 | 1.24 | 1.92 | |
| Intangibles to total assets | 0.03 | 0.05 | 0.05 | 0.04 | 0.03 | |
| Capex to operating cash flow | 0.29 | 0.18 | 0.06 | -0.12 | 0.06 | |
| Capex to revenue | -1.28 | -0.57 | -0.22 | -0.08 | -0.21 | |
| Capex to depreciation | -9.42 | -3.27 | -0.31 | -0.32 | -0.45 | |
| Stock based compensation to revenue | 0.34 | 0.15 | 0.21 | 0.16 | 0.71 | |
| Graham number | 6.45 | 7.56 | 6.8 | 3.33 | 0.5 | |
| ROIC | -0.2 | -0.5 | -0.42 | -0.27 | -0.41 | |
| Return on tangible assets | -0.2 | -0.44 | -0.39 | -0.19 | -0.31 | |
| Graham Net | 2.21 | 0.78 | 0.29 | 0.11 | 0.07 | |
| Working capital | 10.7M | 7.11M | 7.81M | 8.58M | 17.26M | |
| Tangible asset value | 9.83M | 6.87M | 7.46M | 6.28M | 13.34M | |
| Net current asset value | 9.12M | 4.73M | 3.94M | 3.42M | 10.95M | |
| Invested capital | 0.17 | 0.38 | 0.58 | 0.98 | 0.53 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 911.5K | 1.14M | 1.04M | 1.41M | 1.44M | |
| Average inventory | 220.5K | 219.5K | 300K | 313K | 366.5K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 1.99K | 803.37 | 14.49K | 128.48K | 1.28K | |
| Days of inventory on hand | 614.74 | 115.55 | 6.16K | 28.56K | 367.63 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.18 | 0.45 | 0.03 | 0 | 0.29 | |
| Inventory turnover | 0.59 | 3.16 | 0.06 | 0.01 | 0.99 | |
| ROE | -0.24 | -0.67 | -0.67 | -0.54 | -0.61 | |
| Capex per share | -0.17 | -0.22 | -0.06 | -0.04 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2019-06-30 for Q2
| Metric | History | 2017-06-30 | 2018-06-30 | 2019-06-30 |
|---|---|---|---|---|
| Revenue per share | 0.03 | 0.1 | 0.07 | |
| Net income per share | -0.17 | -0.33 | -0.29 | |
| Operating cash flow per share | -0.15 | -0.3 | -0.26 | |
| Free cash flow per share | -0.19 | -0.35 | -0.28 | |
| Cash per share | 3.41 | 2.07 | 0.83 | |
| Book value per share | 3.3 | 2.18 | 1.01 | |
| Tangible book value per share | 3.3 | 1.96 | 1.01 | |
| Share holders equity per share | 3.3 | 2.18 | 1.01 | |
| Interest debt per share | 0.32 | 0.44 | 0.99 | |
| Market cap | 36.48M | 27.91M | 16.67M | |
| Enterprise value | 25.13M | 21.67M | 17.33M | |
| P/E ratio | -14.93 | -5.62 | -3.03 | |
| Price to sales ratio | 296.6 | 76.26 | 50.9 | |
| POCF ratio | -67.19 | -24.56 | -13.48 | |
| PFCF ratio | -52.06 | -20.73 | -12.74 | |
| P/B Ratio | 3.02 | 3.37 | 3.52 | |
| PTB ratio | 3.02 | 3.37 | 3.52 | |
| EV to sales | 204.29 | 59.2 | 52.92 | |
| Enterprise value over EBITDA | -43.7 | -18.73 | -16.46 | |
| EV to operating cash flow | -46.28 | -19.07 | -14.02 | |
| EV to free cash flow | -35.86 | -16.09 | -13.24 | |
| Earnings yield | -0.02 | -0.04 | -0.08 | |
| Free cash flow yield | -0.02 | -0.05 | -0.08 | |
| Debt to equity | 0.09 | 0.18 | 0.86 | |
| Debt to assets | 0.14 | 0.25 | 0.58 | |
| Net debt to EBITDA | 19.75 | 5.4 | -0.63 | |
| Current ratio | 16.94 | 7.22 | 2.87 | |
| Interest coverage | -31.33 | -58.57 | -14.33 | |
| Income quality | 0.89 | 0.92 | 0.9 | |
| Dividend Yield | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | |
| Research and developement to revenue | 2.29 | 1.21 | 3.03 | |
| Intangibles to total assets | 0 | 0.07 | 0 | |
| Capex to operating cash flow | 0.29 | 0.18 | 0.06 | |
| Capex to revenue | -1.28 | -0.57 | -0.22 | |
| Capex to depreciation | -9.42 | -3.27 | -0.31 | |
| Stock based compensation to revenue | 0.34 | 0.15 | 0.21 | |
| Graham number | 3.52 | 4 | 2.58 | |
| ROIC | -0.05 | -0.12 | -0.14 | |
| Return on tangible assets | -0.04 | -0.12 | -0.12 | |
| Graham Net | 2.89 | 1.36 | -0.57 | |
| Working capital | 12.77M | 8.04M | 4.61M | |
| Tangible asset value | 0 | 7.47M | 0 | |
| Net current asset value | 11.65M | 6.56M | 413K | |
| Invested capital | 0.09 | 0.2 | 0.96 | |
| Average receivables | 0 | 0 | 0 | |
| Average payables | 1.03M | 1.06M | 1.11M | |
| Average inventory | 242K | 266.5K | 288.5K | |
| Days sales outstanding | 0 | 0 | 0 | |
| Days payables outstanding | 2.86K | 590.65 | 16.14K | |
| Days of inventory on hand | 303.16 | 102.21 | 3.32K | |
| Receivables turnover | 0 | 0 | 0 | |
| Payables turnover | 0.03 | 0.15 | 0.01 | |
| Inventory turnover | 0.3 | 0.88 | 0.03 | |
| ROE | -0.05 | -0.15 | -0.29 | |
| Capex per share | -0.04 | -0.06 | -0.02 |
Frequently Asked Questions
What is Valbiotis SA stock symbol ?
Valbiotis SA is a FR stock , located in Perigny of Nouvelle-aquitaine and trading under the symbol ALVAL.PA
What is Valbiotis SA stock quote today ?
Valbiotis SA stock price is $3.66 today.
Is Valbiotis SA stock public?
Yes, Valbiotis SA is a publicly traded company.
Company Profile
- Volume Average 6.35K
- Market Capitalization 45.42M
- Employee 5K
- CEO Mr. Sbastien Peltier
- Headquarters Perigny,NOUVELLE-AQUITAINE,FR
- IPO Date 2017-06-07
-
Website
https://www.valbiotis.com 
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
